bpc-157 fda approved 2025 and other peptides are everywhere in the fitness world right now. The anecdotal reports (and some early research) are exciting! But, we still need to approach BPC-157 with caution. Right now An FDA advisory panel voted

Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL 14736, Pliva) Current Pharmaceutical Design Comprehensive review of BPC 157 clinical development for inflammatory bowel disease including ulcerative colitis trials, demonstrating mucosal healing and anti-inflammatory effects across multiple organ systems

Maximum potency requirements favor injection

(29,30,31) CTGF: Supports connective tissue

weekly, biweekly, or monthly injections are common depending on deficiency and goals

Chronic activation of these glial cells drives neuroinflammatory processes that accelerate neurodegeneration, making their modulation a critical therapeutic target